Table 1. Clinical and serological characteristics of systemic sclerosis patients.
| Author | Design | Controls | n | Age mean/median (years) | Disease duration mean/median (years) | Female n(%) | Diffuse n(%) | SCL70 n(%) | ACA n(%) | Other |
|---|---|---|---|---|---|---|---|---|---|---|
| Stratton et al.[19] | P | No | 13 | NA/52 | NA/0.75 | 10 (77) | 13(100) | 2(15) | 0 | U1 RNP 2(15) U3 RNP 1(8) RNA PIII 2(15) |
| Vanthuyne et al.[25] | P | No | 16 | 47/NA | 0.8/NA | 12 (75) | 13(81) | NA | NA | NA |
| Nihtyanova et al.[27] | R | Yes | 109 | NA/NA | NA | 90(83) | 101(93) | 35(32.1) | 2(1.8) | U3 RNP 5(4.6) RNA PIII 26(23.9) |
| Le et al.[31] | R | Yes | 98 | 48.4/NA | 1.83/NA | 81 (83) | 98(100) | 24(24) | 2(2) | NA |
| Mendoza et al.[20] | P | No | 25 | 48.6/NA | 14.1/NA | NA | 25(100) | 9(36) | 0 | NA |
| Cuomo et al.[36] | C | No | 1 | 63/NA | 7/NA | 1 (100) | 1(100) | NA | NA | NA |
| Saketkoo et al.[37] | C | No | 4 | 50.5/55.5 | 6.25/6 | 4 (100) | NA | NA | NA | NA |
| Zamora et al.[28] | R | No | 17 | 50.8/NA | NA/2 | 10 (59) | 15(88) | NA | NA | NA |
| Gerbino et al.[26] | R | No | 13 | NA/52 | NA/5 | 8 (62) | 9(69) | 4(31) | Na | NA |
| Derk et al.[21] | P | No | 15 | 50/NA | 1.1/NA | 10 (66.7) | 15(100) | 6(40) | 0 | NA |
| Koutroumpas et al.[29] | R | No | 10 | 59.7/NA | 7.7/NA | 8 (80) | 10(100) | 10(100) | 0 | NA |
| Simeón-Aznar et al.[22] | P | No | 14 | NA/54.4 | NA/6.5 | 13 (93) | 8(57) | 8(57) | 1(7) | NA |
| Liossis et al.[24] | P | No | 6 | 46/NA | 3.4/NA | 4 (66.7) | 6(100) | 6(100) | 0 | NA |
| Plastiras et al.[33] | C | Yes | 7 | 58/NA | NA | 6 (86) | NA | Na | Na | NA |
| Busquets et al.[34] | C | No | 1 | NA/39 | NA/0.67 | NA | 1(100) | NA | NA | NA |
| Bandelier et al.[39] | C | No | 1 | 63/NA | 4/NA | 1 (100) | 1(100) | NA | NA | NA |
| Bérezné et al.[30] | R | No | 5 | NA/NA | NA | NA | NA | NA | NA | NA |
| Gonzalez-Nieto et al.[43] | C | No | 5 | NA/NA | NA | NA | NA | NA | Na | NA |
| Gulamhusein et al.[38] | C | No | 2 | 52/NA | NA | 1 (50) | 2(100) | Na | Na | NA |
| Herrick et al.[23] | ||||||||||
| Protocol 1 | P | Yes | 29 | NA/55.1 | NA | 18 (62) | 29(100) | 8(33) | NA | RNA PIII 1(8) |
| Protocol 2 | P | Yes | 25 | NA/52.7 | NA | 20 (80) | 25(100) | 5(20) | NA | RNA PIII 1(4) |
| Protocol 3 | P | Yes | 61 | NA | 44(72) | 61(100) | 14(24) | NA | RNA PIII 9(22) | |
| Panopoulos et al.[32] | CC | Yes | 26 | 48/NA | 5.8 | 24 (92) | 18 (69) | 19 (73) | NA | NA |
P: Prospective, R: Retrospective, C: Case report/series, CC Case-control, ACA: Anti-centromere antibody, RNA PIII: RNA polymerase III, CAU: Caucasians, AA: African American, CAR: Caribbean, NA: Not available